ARAUJO, Edmar A.S. de
and
FREITAS, Marcos R. Gomes de. Benefit with methylprednisolone in continuous pulsetherapy in progressive primary form of multiple sclerosis: study of 11 cases in 11 years. Arq. Neuro-Psiquiatr. [online].
2008,
vol.66, n.2b, pp. 350-353.
ISSN 0004-282X.
http://dx.doi.org/10.1590/S0004-282X2008000300013.
|
|
2. Lublin FD, Reingold SC. Defining clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911. [ Links ] 3. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005;65:1919-1923. [ Links ] 4. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 129:584-594. [ Links ] 5. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. Optic Neuritis Study Group. N Engl J Med 1992;326:581-588. [ Links ] 6. Beck RW, Cleary PA. Optic Neuritis Study Group. Optic Neuritis Treatment Trial: one- year follow-up results. Arch Ophthalmol 1993;11:73-75. [ Links ] 7. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Neurology 1997;49:1404-1413. [ Links ] 8. Zivadinov R, Rudick RA, De Masi R et al. Effects of IV methilprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-1247. [ Links ] 9. Then Bergh F, Kumpfel T, Schumann E, et al. Montly intravenous methylprednisolone in relapsing-remitting multiple sclerosis: reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol 2006;23:6-19. [ Links ] 10. Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005;11:425-432. [ Links ] 11. Roitt IM, Brostoff J, Male DK. Imunologia. Trad. Jacob Israel Lemos. São Paulo: Ed. Manole, 1989. [ Links ] 12. Bracken MB, Shepard MJ, Collins WF, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. J Neurosurg 1992;76:23-31. [ Links ] 13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452. [ Links ] 14.Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocol. Ann Neurol 1983;13:227-231. [ Links ] 15. Mc Donald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127. [ Links ] 16. Zephir H, de Seze J, Duhamel A, et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 2004;218:73-77. [ Links ] 17. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose metylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-516. [ Links ] 18. Bergamaschi R, Versino M, Raiola E, Citterio A, Cosi V. High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients: one year follow-up. Acta Neurol (Napoli) 1993;15:33-43. [ Links ] 19. Cazzato G, Mesiano T, Antonello R, et al. Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur Neurol 1995;35:193-198. [ Links ] 20. Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998;51:239-245. [ Links ] 21. Zingler VC, Strupp M, Jahn K, Gross A, Holfeld R, Brandt T. The effect of combined mitoxantrone and methylprednisolone theraphy in primary and secondary progressive multiple sclerosis: an applied study in 65 patients. Nervenarzt 2005;76:740-747. [ Links ] 22. Delmont E, Chanelet S, Bourg V, Soriani MH, Chatel M, Lebrun C. Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response. Rev Neurol (Paris) 2004;160:659-665. [ Links ] 23. Oliveri RL, Valentino P, Russo C, et al. Randomized trial comparing two different doses of methylprednisolone in MS. Neurology 1998;50:1833-1836. [ Links ] 24. Fierro B, Salemi G, Brighina F, et al. A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis. Acta Neurol Scand 2002;105:152-157. [ Links ] 25. Sellebjerg F. Methylprednisolone treatment, immune activation, and intrathecal inflammation in multiple sclerosis. Danish Med Bull 2004;51:167-183. [ Links ] |
